[Global Times] Chinese pharmaceutical companies enter the golden age of generic drugs and strive to compete with India

China's generic drug industry has entered a golden era with growing innovative capability and Chinese drug companies are expected to ensure their industrial counterparts in the near future, Recently, China's phenomenal black comedy film "I am not the God of medicine" was released in major cinemas in mainland China After its release, it triggered a heated discussion about cheap Indian generic drugs import and domestic generic drug manufacturing industry "China's generic pharmaceutical industry has entered a golden age of continuous improvement in innovation capacity, and Chinese pharmaceutical companies are expected to surpass their Indian counterparts in the near future," the Global Times said in an interview with industry insiders on July 10 The comments came after the Chinese black comedy Dying to Survive, which hit Chinese mainland theaters Thursday, set off a nationwide debate about cheap Indian generic drug imports and the domestic generic drug manufacturing industry.  Shares of major pharmaceutical firms showed good performance on Tuesday, At the same time, affected by the industry concerns brought by the film, the stock prices of major domestic pharmaceutical companies performed well on Tuesday, with Jiangsu Hengrui medicine up by 0.82 percent, while those of Sino biopharmaceutical group were up 0.84 percent as of closing "Indian generic drugs, especially anti-cancer drugs, are of high quality and low price, while domestic generic drugs have long been criticized for their" unreliable "quality," Cai Jiangnan, a medical researcher at CEIBS, told the global times on Tuesday Domestic generic companies are also reluctant to produce high-quality generic drugs because of their low profits "India's generic drugs, especially anti-cancer ones, are cheaper and of good quality, while domestic generic drugs have long been criticized for their 'unreliable' quality Domestic generic drug manufacturers are also reluctant to produce high-quality drugs due to low profits," Cai Jiangnan, a healthcare research fellow at the China Europe International Business School, told the Global Times on Tuesday.  India is the largest provider of generic drugs globally, with Indian generics accounting for 20 percent of global exports in terms of volume, said a report published on the website of the India Brand Equity Foundation.   "In India, generic drugs are not subject to a patent protection period, thus enjoying a policy advantage in the earlier stage, making it stronger, "Cai told the global times on Tuesday Cai added that China should not copy this" international path "Because generic drugs are not limited by patent protection period in India, they enjoy policy advantages in the early stage of drug R & D and listing, which makes Indian generic manufacturing industry more powerful," said Cai Jiangnan, who also said that "China cannot copy this" unconventional approach "supported by Indian government policy." But there are some things that China should learn from, for example, clear policy guidance, said Li Tianquan, co-founder of domestic healthcare big data platform yaozh.com Some Indian pharmaceutical companies have opened a sales channel to Europe and the US by targeting high-quality generic drugs, Li told the Global Times Tuesday China is now heading in the right direction, as Chinese regulators have been regulating the drug review process, and domestic drug companies have also been improving their innovative abilities, according to Li Li also pointed to the method of consistency evaluation for generic drugs, which was released by the China Food and Drug Administration in 2016 to evaluate the quality and effect of generic drugs, saying that "the evaluation method would ensure quality of domestic drug products, "And Li Tianquan, co-founder of China's pharmaceutical big data service platform, pharmaceutical intelligence network, said that China should learn something from it, such as clear policy guidance." "Some Indian generic companies have opened up sales channels to Europe and the United States by targeting high-quality generic drugs," Li told the global times on Tuesday At the same time, China is now moving in the right direction, because China's regulatory agencies have been controlling the drug review process layer by layer, and domestic pharmaceutical companies have also timely and constantly improved their R & D and innovation capabilities " Li Tianquan also pointed out the method for evaluating the consistency of quality and efficacy of generic drugs issued by China food and Drug Administration in 2016, which said that "the evaluation method will ensure the quality of domestic generic drugs and lead the industry to a more perfect development model." The country's leading pharmaceutical firms have already made some breakthroughs For example, Jiangsu Hansoh Pharmaceutical Group told the Global Times on Tuesday that Xinwei, a generic anti-cancer drug it produces, has officially passed the country's consistency evaluation for generic drugs, proving that its quality and effects could already compare to the original drug Gleevec, which is produced by Swiss pharmaceutical giant Novartis "With almost the same effect, we sell for only one-tenth of the price of Gleevec," said the company.  Data showed that in 2017, the sales volume for Xinwei was 210 million yuan, accounting for a market share of 10 percent, while at the same time, the sales volume for Gleevec was 1.5 billion yuan, with almost 80 percent of the market Li said the market share for generic drugs is expected to surpass 50 percent as soon as the drugs pass the consistency inspection "We are in the best era for developing and producing drugs in China, which we feel Lucky about, "said the hansoh group." it's not realistic to ensure industry in the short-term, but in eight or ten years, there will be a breakthrough in the domestic generic drug industry, "Li said For example, in an interview with the global times on July 10, the head of Jiangsu Haosen Pharmaceutical Group said that the generic anticancer drug "Xinwei" produced by its company has officially passed the generic consistency evaluation, proving that its quality and effect can be compared with the original drug "Gleevec" produced by Novartis, a Swiss pharmaceutical giant And the price of the generic drug is only one tenth of that of "Gleevec" when it has the same efficacy According to the data, in 2017, the sales volume of "Xinwei" was RMB 210 million, accounting for 10% of the market share, while the sales volume of "Gleevec" was RMB 1.5 billion, accounting for nearly 80% of the market share Li Tianquan further said in the interview that once the generic drugs pass the consistency evaluation, its market share is expected to exceed 50% The head of hausen group said that we are in the best era of drug R & D and production in China, and we feel very lucky about that Li said in an interview that it is unrealistic for the domestic generic pharmaceutical industry to surpass India in the short term, but there may be new breakthroughs in the next decade and eight years Steven, king of medicine, click here to enter the English version of Global Times~